Carlos A. DiazGranados

Bill & Melinda Gates Foundation — United States

Medicine · Health Sciences

32h-index6.1kcitations92works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Influenza Virus Research Studies(20), Mosquito-borne diseases and control(18), HIV Research and Treatment(14), Respiratory viral infections research(14), Viral Infections and Vectors(12)

Publications90 total

Accelerating Innovation: Advancing Opportunities in HIV Vaccine Development
Current HIV Research·2025
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1–2 randomized double-blind placebo-controlled trial
PLOS Global Public Health·2024Open Access
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial
PLoS Medicine·2024· 8 citedOpen Access
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120
The Journal of Infectious Diseases·2023· 6 citedOpen Access
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
The Lancet Respiratory Medicine·2023· 23 citedOpen Access
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
EClinicalMedicine·2023· 11 citedOpen Access
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
2022· 15 citedOpen Access
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
Zenodo (CERN European Organization for Nuclear Research)·2022Open Access
Analysis of the HIV Vaccine Trials Network 702 Phase 2b–3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk
The Journal of Infectious Diseases·2022· 47 citedOpen Access
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials
The Lancet Microbe·2022· 11 citedOpen Access
Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study
2021· 2 citedOpen Access
Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials
The Journal of Infectious Diseases·2021· 6 citedOpen Access
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
The Lancet Infectious Diseases·2021· 123 citedOpen Access
Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America
Clinical Infectious Diseases·2021· 22 citedOpen Access
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study
2021· 7 citedOpen Access
Accuracy, efficacy and safety of dengue CYD-TDV pre-vaccination screening with 5 existing IgG serotests: Retrospective analysis of phase III trials
International Journal of Infectious Diseases·2020Open Access
Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries
Transactions of the Royal Society of Tropical Medicine and Hygiene·2020· 4 citedOpen Access
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials
The Lancet Infectious Diseases·2020· 24 citedOpen Access
Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9–50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study
The Lancet Infectious Diseases·2020· 18 cited
Zika and Dengue Interactions in the Context of a Large Dengue Vaccine Clinical Trial in Latin America
American Journal of Tropical Medicine and Hygiene·2020· 8 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Matthew Bonaparte(11), Stephen J. Savarino(10), Peter B. Gilbert(10), Victoria Landolfi(8), Georgia D. Tomaras(8), Sanjay Gurunathan(7), Linda‐Gail Bekker(7), Marguerite Koutsoukos(7), Nicole Grunenberg(7), Sanjay Phogat(7), Lawrence Corey(7), M. Juliana McElrath(7), Gustavo H. Dayan(7), Andrew J. Dunning(6), David P. Greenberg(6), H. Keipp Talbot(6), Zoe Moodie(6), Fernando Noriega(6), Nelson L. Michael(6), Merlin L. Robb(6)